Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Ind-Ra maintains a neutral outlook for healthcare in FY23
Ind-Ra expects revenue growth of over 12% in 2022.
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
During H1 FY2022, the revenues and operating profit margin (OPM) for ICRA sample set showed sharp improvement aided by volume uptick in Covid-19 and allied tests and also demand traction for non-Covid tests
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Subscribe To Our Newsletter & Stay Updated
